Growth Metrics

Ceribell (CBLL) Equity Ratio (2023 - 2026)

Ceribell posted quarterly Equity Ratio of 0.79 for Q1 2026, down 6.68% year-on-year from 0.85 in Q1 2025, and little changed on a QoQ basis from 0.79 in Q4 2025.

Ceribell (CBLL) has 4 years of Equity Ratio data on file, last reported at 0.79 in Q1 2026.

  • For the quarter ending Q1 2026, Equity Ratio fell 6.68% year-over-year to 0.79; the trailing twelve-month figure through Mar 2026 stood at 0.79 (down 6.68% YoY), and the FY2025 full-year result was 0.79, down 6.45% from the prior year.
  • Equity Ratio for Q1 2026 stood at 0.79, roughly flat from 0.79 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.85 in Q4 2024 and bottomed at 2.89 in Q3 2024.
  • The 4-year median for Equity Ratio is 0.81 (2025), against an average of 0.02.
  • The widest annual swing landed in 2024, when Equity Ratio surged 144.52%; it then slipped 6.68% in 2026.
  • A 4-year view of Equity Ratio shows it stood at 1.91 in 2023, then soared by 144.52% to 0.85 in 2024, then fell by 6.45% to 0.79 in 2025, then fell by 0.33% to 0.79 in 2026.
  • The last three Equity Ratio figures came in at 0.79 (Q1 2026), 0.79 (Q4 2025), and 0.82 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 0.47
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 0.50
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 0.54
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 0.59
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 0.78
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 0.45
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 0.29
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 0.67
10 Ceribell 666.26 Mn 525.07 Mn 23.12 Mn 0.79

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.79
Dec 31, 2025 0.79
Sep 30, 2025 0.82
Jun 30, 2025 0.83
Mar 31, 2025 0.85
Dec 31, 2024 0.85
Sep 30, 2024 -2.89
Dec 31, 2023 -1.91